Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bacterial Infections and Mycoses

Free Subscription Articles published in Lancet Retrieve available abstracts of 61 articles: HTML format

Single Articles

February 2026
1. ERGONUL O, Kolsuz S, Figueroa JP
   Tetanus.
   Lancet. 2026;407:716-727.
   PubMed     Abstract available
   
   
   December 2025
2. HUI D, Sahu S, Ditiu L, Marais BJ, et al
   Global tuberculosis response off track: urgent priorities to end the world's top infectious killer.
   Lancet. 2025 Dec 11:S0140-6736(25)02433-X. doi: 10.1016/S0140-6736(25)02433.
   PubMed    
   
   
   
3. LUCKEY A, Balasegaram M, Barbee LA, Batteiger TA, et al
   Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
   Lancet. 2025 Dec 11:S0140-6736(25)01953-1. doi: 10.1016/S0140-6736(25)01953.
   PubMed     Abstract available
   
   
   
4. LATEEF S
   Aid cuts hampering Nepal's tuberculosis care.
   Lancet. 2025 Dec 4:S0140-6736(25)02469-9. doi: 10.1016/S0140-6736(25)02469.
   PubMed    
   
   
   October 2025
5. BURDET C, Saidani N, Dupieux C, Lemaignen A, et al
   Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
   Lancet. 2025 Oct 17:S0140-6736(25)01624-1. doi: 10.1016/S0140-6736(25)01624.
   PubMed     Abstract available
   
   
   
6. HENDRICK J, Raqib R, Noor Z, Faruque ASG, et al
   Shigellosis.
   Lancet. 2025;406:1508-1519.
   PubMed     Abstract available
   
   
   September 2025
7. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
   Enteric (typhoid and paratyphoid) fever.
   Lancet. 2025;406:1283-1294.
   PubMed     Abstract available
   
   
   August 2025
8. DROBNIEWSKI F, Kon OM, Gonzalo X, Ashmi M, et al
   Why are we failing to rapidly diagnose tuberculosis in the UK?
   Lancet. 2025;406:908-909.
   PubMed    
   
   
   July 2025
9. ABUZERR S, Hamdan H, Charafeddine J
   Paediatric meningitis outbreak in Gaza amid health system collapse.
   Lancet. 2025 Jul 31:S0140-6736(25)01520-X. doi: 10.1016/S0140-6736(25)01520.
   PubMed    
   
   
   
10. MACIEL EL, Pablos-Mendez A, Abubakar I
    Undoing progress through sudden tuberculosis funding cuts.
    Lancet. 2025 Jul 3:S0140-6736(25)01328-5. doi: 10.1016/S0140-6736(25)01328.
    PubMed    
    
    
    
11. HALLETT TB, Menzies NA, Resch S, Pretorius C, et al
    The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study.
    Lancet. 2025 Jul 3:S0140-6736(25)00831-1. doi: 10.1016/S0140-6736(25)00831.
    PubMed     Abstract available
    
    
    June 2025
12. HIRANI K, Rwebembera J, Webb R, Beaton A, et al
    Acute rheumatic fever.
    Lancet. 2025;405:2164-2178.
    PubMed     Abstract available
    
    
    
13. AL ZAMEL AM, Saeed AA, Elmubarak M, Alsarraj MA, et al
    Sudan's tuberculosis response needs global support amid conflict.
    Lancet. 2025 Jun 2:S0140-6736(25)01119-5. doi: 10.1016/S0140-6736(25)01119.
    PubMed    
    
    
    May 2025
14. HABTAMU E, Harding-Esch EM, Greenland K, Wamyil-Mshelia T, et al
    Trachoma.
    Lancet. 2025;405:1865-1878.
    PubMed     Abstract available
    
    
    
15. SUNDAR R, Nakayama I, Markar SR, Shitara K, et al
    Gastric cancer.
    Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052.
    PubMed     Abstract available
    
    
    April 2025
16. ROSS JDC, Wilson J, Workowski KA, Taylor SN, et al
    Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
    Lancet. 2025 Apr 11:S0140-6736(25)00628-2. doi: 10.1016/S0140-6736(25)00628.
    PubMed     Abstract available
    
    
    
17. KLUGE HHP
    Tuberculosis: a threat to health security in the European region and the collective actions needed.
    Lancet. 2025 Apr 7:S0140-6736(25)00677-4. doi: 10.1016/S0140-6736(25)00677.
    PubMed    
    
    
    March 2025
18. DHEDA K, Perumal T, Fox GJ
    Asymptomatic tuberculosis: undetected and underestimated, but not unimportant.
    Lancet. 2025 Mar 21:S0140-6736(25)00555-0. doi: 10.1016/S0140-6736(25)00555.
    PubMed    
    
    
    
19. JERENE D, van Kalmthout K, Levy J, Alacapa J, et al
    Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
    Lancet. 2025 Mar 11:S0140-6736(24)02847-2. doi: 10.1016/S0140-6736(24)02847.
    PubMed     Abstract available
    
    
    
20. MARX FM, Civan A
    Rethinking the benefits of digital adherence technologies for tuberculosis treatment.
    Lancet. 2025 Mar 11:S0140-6736(25)00199-0. doi: 10.1016/S0140-6736(25)00199.
    PubMed    
    
    
    
21. TROTTER C, Diallo K
    Another step towards defeating meningitis.
    Lancet. 2025 Mar 11:S0140-6736(25)00196-5. doi: 10.1016/S0140-6736(25)00196.
    PubMed    
    
    
    
22. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    PubMed     Abstract available
    
    
    
23. TRAJMAN A, Campbell JR, Kunor T, Ruslami R, et al
    Tuberculosis.
    Lancet. 2025;405:850-866.
    PubMed     Abstract available
    
    
    February 2025
24. ZUMLA A, Sahu S, Yeboah-Manu D, Goletti D, et al
    Breaking dependency: strengthening the global tuberculosis response in the face of USAID cuts.
    Lancet. 2025 Feb 26:S0140-6736(25)00335-6. doi: 10.1016/S0140-6736(25)00335.
    PubMed    
    
    
    
25. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    PubMed     Abstract available
    
    
    January 2025
26. MACESIC N, Uhlemann AC, Peleg AY
    Multidrug-resistant Gram-negative bacterial infections.
    Lancet. 2025;405:257-272.
    PubMed     Abstract available
    
    
    October 2024
27. BHARGAVA A, Bhargava M, Velayutham B, Benedetti A, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial - Authors' reply.
    Lancet. 2024;404:1524.
    PubMed    
    
    
    
28. ZHANG K, Xu Y, Hu Y, Chen X, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1523-1524.
    PubMed    
    
    
    
29. BUSANG J, Khan P
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522-1523.
    PubMed    
    
    
    
30. RICKMAN HM, Yates TA
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522.
    PubMed    
    
    
    
31. KAUR JABINDA M
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1521-1522.
    PubMed    
    
    
    
32. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    PubMed     Abstract available
    
    
    
33. BHATTARAI MD
    Utilising available isoniazid-resistance tests in new patients.
    Lancet. 2024;404:1403.
    PubMed    
    
    
    
34. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    PubMed    
    
    
    September 2024
35. KHAN M
    "The final warning sign": XDR typhoid.
    Lancet. 2024;404:1182-1183.
    PubMed    
    
    
    
36. VAN RHIJN N, Arikan-Akdagli S, Beardsley J, Bongomin F, et al
    Beyond bacteria: the growing threat of antifungal resistance.
    Lancet. 2024;404:1017-1018.
    PubMed    
    
    
    
37. 
    Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.
    Lancet. 2024 Sep 13:S0140-6736(24)01867-1. doi: 10.1016/S0140-6736(24)01867.
    PubMed     Abstract available
    
    
    
38. HIRATE T, Kanda K, Ohshima Y, Shinoda K, et al
    Congenital syphilis in a 2-month-old infant during Japanese outbreak.
    Lancet. 2024;404:971.
    PubMed    
    
    
    August 2024
39. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    PubMed    
    
    
    
40. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    PubMed    
    
    
    July 2024
41. LI M, Kim JB, Sastry BKS, Chen M, et al
    Infective endocarditis.
    Lancet. 2024;404:377-392.
    PubMed     Abstract available
    
    
    June 2024
42. HYDE L
    Mobile screening for Ukraine's wartime tuberculosis epidemic.
    Lancet. 2024;403:2771.
    PubMed    
    
    
    
43. MCCANN N, Vicentine MP, Pollard AJ
    Towards paratyphoid control: the vital role of the challenge model.
    Lancet. 2024;403:2780-2781.
    PubMed    
    
    
    
44. CRENNER C
    Ulcers, stress, and the discovery of Helicobacter pylori.
    Lancet. 2024;403:2586-2587.
    PubMed    
    
    
    
45. WHITE NJ
    Death from diphtheria.
    Lancet. 2024;403:2590-2591.
    PubMed    
    
    
    
46. LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al
    40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention.
    Lancet. 2024;403:2570-2572.
    PubMed    
    
    
    
47. ALMADI MA, Lu Y, Alali AA, Barkun AN, et al
    Peptic ulcer disease.
    Lancet. 2024 Jun 14:S0140-6736(24)00155-7. doi: 10.1016/S0140-6736(24)00155.
    PubMed     Abstract available
    
    
    
48. MARIONI G, Franz L, Incognito A, Bitonti S, et al
    Bilateral simultaneous cochlear implant in an adult with anacusis due to bacterial meningitis.
    Lancet. 2024;403:2533.
    PubMed    
    
    
    
49. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    PubMed    
    
    
    
50. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    PubMed    
    
    
    May 2024
51. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed     Abstract available
    
    
    
52. LEWNARD JA, Charani E, Gleason A, Hsu LY, et al
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet. 2024 May 20:S0140-6736(24)00862-6. doi: 10.1016/S0140-6736(24)00862.
    PubMed     Abstract available
    
    
    
53. OKEKE IN, de Kraker MEA, Van Boeckel TP, Kumar CK, et al
    The scope of the antimicrobial resistance challenge.
    Lancet. 2024 May 20:S0140-6736(24)00876-6. doi: 10.1016/S0140-6736(24)00876.
    PubMed     Abstract available
    
    
    
54. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed     Abstract available
    
    
    
55. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    PubMed    
    
    
    March 2024
56. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    PubMed    
    
    
    
57. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    PubMed     Abstract available
    
    
    
58. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    PubMed    
    
    
    
59. BHARGAVA A, Bhargava M, Pai M
    Tuberculosis: a biosocial problem that requires biosocial solutions.
    Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
    PubMed    
    
    
    
60. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    PubMed    
    
    
    
61. SUBBARAMAN R, Fielding K
    Putting technology to the test in tuberculosis care.
    Lancet. 2024;403:878-879.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bacterial Infections and Mycoses is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum